PI Industries Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript PI Industries Ltd filed with BSE on 18 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
PI Industries reported Q1 FY27 revenue of Rs. 17,023 million with a gross margin of 57% and EBITDA margin of 22%, as domestic volumes grew 12% while export revenue declined amid soft commodity prices and pricing pressure. Biologicals grew 50% year-on-year with a three-year CAGR of 15%, while the pharma and global biologicals businesses continued to post losses tied to upfront investment. Management reiterated capex guidance of Rs. 700-800 crore for the year and said it expects FY27 to be better than FY26, driven by an export recovery in the second half.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue: Rs. 17,023 million (Q1 FY27)
p. 5
“For Q1 FY27, reported revenue is Rs. 17,023 million with a healthy gross margin of 57% and EBITDA at 22%.”
Sanjay Agarwal, page 5 of the filed PDF · View the filing
EBITDA: INR 3,693 million (Q1 FY27)
p. 6
“EBITDA for the quarter stood at INR 3,693 million, translating into an EBITDA margin of 22%.”
Sanjay Agarwal, page 6 of the filed PDF · View the filing
Biologicals growth: 50% (Q1 FY27)
p. 6
“Biologicals have shown an aggressive growth of 50% with a three-year CAGR of 15%.”
Sanjay Agarwal, page 6 of the filed PDF · View the filing
Domestic volume growth: 12% (Q1 FY27)
p. 6
“Despite a challenging operating environment in the domestic market, we delivered a 12% volume growth in this quarter, translating into a 3% revenue growth.”
Sanjay Agarwal, page 6 of the filed PDF · View the filing
Net working capital reduction: 19 days, releasing INR 300 crore of cash (Q1 FY27)
p. 7
“the team delivered an impressive reduction of 19 days in net working capital, releasing INR 300 crore of cash.”
Sanjay Agarwal, page 7 of the filed PDF · View the filing
Net cash: INR 38 billion
p. 7
“Our strong debt-free balance sheet, supported with net cash of INR 38 billion, provides resilience and flexibility for strategic investments.”
Sanjay Agarwal, page 7 of the filed PDF · View the filing
Order book: $1.2 billion
p. 13
“I think you cited a number of $1.2 billion previously, a little earlier on the call.”
Abhijit Akella, page 13 of the filed PDF · View the filing
Contract asset: Rs. 750 odd crore (June 2026)
p. 10
“It is around Rs. 750 odd crore.”
Sanjay Agarwal, page 10 of the filed PDF · View the filing
New products contribution to CSM segment: 16% to 18% (Q1 FY27)
p. 10
“16% to 18%.”
Sanjay Agarwal, page 10 of the filed PDF · View the filing
Q1 capex: Rs. 250 crore (Q1 FY27)
p. 11
“Our present investment is Rs. 250 crore.”
Mayank Singhal, page 11 of the filed PDF · View the filing
Export volume decline: 8% (Q1 FY27)
p. 11
“so we have mentioned that there is a volume decline of 8% while value decline is 12%”
Surya Narayan, page 11 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Full year capex — Rs. 700 to Rs. 800 crore · FY27
stated firmly by Mayank Singhal
p. 11
“We have given a guidance of Rs. 700 to Rs. 800 crore, which is the standard capex as you rightly said.”
Mayank Singhal, page 11 of the filed PDF · View the filing
Effective tax rate — around 24% · FY27
stated firmly by Sanjay Agarwal
p. 7
“We expect ETR for FY27 to be around 24%.”
Sanjay Agarwal, page 7 of the filed PDF · View the filing
FY27 performance versus FY26 — FY27
stated conditionally by Sanjay Agarwal
p. 7
“We expect FY27 to be better over FY26 driven by recovery in exports in second half supported by new product launches and gradual scale up of pharma and global biologicals businesses.”
Sanjay Agarwal, page 7 of the filed PDF · View the filing
Revenue growth — lower single digit · FY27
stated conditionally by Mayank Singhal
p. 9
“we are looking at a positive trajectory, and in the lower single digit as indicated earlier.”
Mayank Singhal, page 9 of the filed PDF · View the filing
Pioxaniliprole domestic launch — within the current year
stated conditionally by Mayank Singhal
p. 10
“We are hoping within the year we should get the launch for India.”
Mayank Singhal, page 10 of the filed PDF · View the filing
CRDMO platform evolution — fully integrated CRDMO platform
stated as an aspiration by Sanjay Agarwal
p. 6
“our long-term ambition is to evolve into a fully integrated CRDMO platform, recognizing that such a transition requires patience, capability building, and customer trust.”
Sanjay Agarwal, page 6 of the filed PDF · View the filing
R&D spend as percentage of revenue — 3% to 4%
stated firmly by Mayank Singhal
p. 16
“we remain at that level of a certain percentage, at 3% to 4% investments of our revenues into research.”
Mayank Singhal, page 16 of the filed PDF · View the filing
Brazil nematicide market share — double-digit market share · five to ten years
stated as an aspiration by Mayank Singhal
p. 21
“double-digit market share is not a challenge for that product, and that is where I would park that answer.”
Mayank Singhal, page 21 of the filed PDF · View the filing
Electronic chemicals business scale — a billion dollar play
stated as an aspiration by Mayank Singhal
p. 20
“We are trying to get into a billion dollar play, but significant from our perspective to have entered that space”
Mayank Singhal, page 20 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said the pipeline spans Agchem R&D, CSM, biologicals and electronics with no consolidated breakup available, but described the pipeline as aggressive.
Answered by Mayank Singhal
Asked by Ankur Periwal: How should investors think about the ~90-molecule pipeline across Agchem, Electronics, Pharma and Biologicals?
p. 8
“So, I would say the pipeline is aggressive and it is interesting to see that some of these when they fructify will give us some great positive trajectory in the medium to long-term.”
Mayank Singhal, page 8 of the filed PDF · View the filing
Management maintained its earlier guidance of positive but low single-digit growth, subject to cycle and industry conditions.
Answered by Mayank Singhal
Asked by Tejas Pradhan: What is the FY27 revenue growth guidance?
p. 9
“we are looking at a positive trajectory, and in the lower single digit as indicated earlier. But again, depends on the cycle and the industry, it could go one way or the other, but that is what we are confident for right now and maintain the same as we said earlier.”
Mayank Singhal, page 9 of the filed PDF · View the filing
Management said PI does not disclose patented or unpatented molecules since it operates a CRDMO services model, not a molecule ownership model, and explained CRDMO has a long gestation period.
Answered by Mayank Singhal
Asked by Sanjay Kumar: Has the Archimica acquisition not worked out given the pharma expenses versus capex, and can a list of pharma molecules and their stages be shared?
p. 12
“We are not in the business of molecules. We are in the business of services where we do contract manufacturing for products and drugs which are under development or at early-stage development.”
Mayank Singhal, page 12 of the filed PDF · View the filing
Management attributed the additional loss primarily to global biologicals market development spend on farmer interactions and demonstrations, alongside pharma investments.
Answered by Mayank Singhal
Asked by Riju: What explains the gap between subsidiary-level EBIT loss and the pharma EBITDA loss?
p. 14
“We have 1,000 farmer’s interactions, 500 demonstrations in global geographies and to bring satisfaction over a couple of seasons and that is expected to earn revenue at a later stage.”
Mayank Singhal, page 14 of the filed PDF · View the filing
Management described R&D spend as value creation rather than a loss and said it would remain at 3-4% of revenue, without giving a specific breakeven timeline for the loss-making subsidiaries.
Answered by Mayank Singhal
Asked by Siddharth Gadekar: How should rising R&D expense and subsidiary losses be viewed, and is there a timeline to break even?
p. 16
“I just want to clarify one thing, R&D to us is never a loss. It is a value creation that we are doing.”
Mayank Singhal, page 16 of the filed PDF · View the filing
Jagresh Rana said the global biological market is around $10 billion growing in double digits, with the Brazil nematicide market at roughly $750 million.
Answered by Jagresh Rana
Asked by Anand Jain: What is the size of the nematicide opportunity in Brazil, Mexico and the US?
p. 18
“In Brazil, if you look at it, of the total market, roughly around USD 750 million is the nematicide market.”
Jagresh Rana, page 18 of the filed PDF · View the filing
Management said a commercial plant has begun operations with commercial supplies started using new technology, while acknowledging the segment remains not yet substantial.
Answered by Mayank Singhal
Asked by Anand Jain: What does "commercialized" mean in the electronic chemicals business given years of similar statements without visible revenue impact?
p. 20
“We have put a commercial plant, which has got into operations, and commercial supplies in that area have started with the new technology.”
Mayank Singhal, page 20 of the filed PDF · View the filing
Management said it expects the product to become a three-digit revenue product over time, taking five to seven years to build.
Answered by Mayank Singhal
Asked by Sanjay Kumar: What is the revenue potential of the newly registered Dicloromezotiaz product for diamondback moth?
p. 21
“First commercial launch in the Indian context, I do believe it will be a three-digit product in times to come. It takes five, seven years in that segment to build a product as you would appreciate.”
Mayank Singhal, page 21 of the filed PDF · View the filing
Risks flagged
Delayed sowing and El Nino-driven heatwaves impacted pre-placement and chemical sales in the domestic market
p. 3
“On the domestic front, this year began with El Nino, strong heatwaves, delayed sowing and high level of inventories from prior years.”
Mayank Singhal, page 3 of the filed PDF · View the filing
Margin pressure from high input costs and elevated inventory levels
p. 3
“There are pressure on margins due to high input cost & higher levels of inventory, however we believe consumption patterns will see a positive trajectory.”
Mayank Singhal, page 3 of the filed PDF · View the filing
Export business facing soft commodity prices, muted crop economics recovery, and geopolitical, genericization and tariff pressures
p. 4
“This is further compounded by rising costs due to geopolitical uncertainties, genericization pressures and tariffs.”
Mayank Singhal, page 4 of the filed PDF · View the filing
Pricing pressure across Agrochem CSM and domestic agrochemical business due to weak demand cycle
p. 8
“Just to give you the input to the pricing pressure, you will see that demand cycle has been challenged. Automatically, that puts pressure on price.”
Mayank Singhal, page 8 of the filed PDF · View the filing
Early-stage CRDMO portfolio carries higher volatility due to small scale
p. 15
“We are in the early stages, and have more volatility, to be very honest, because our portfolio levels are very small.”
Mayank Singhal, page 15 of the filed PDF · View the filing
Industry remains cautious about erratic weather and climatic conditions affecting crops and consumption
p. 3
“The industry remains cautious and watchful of erratic weather and climatic situations which will impact crops and consumption.”
Mayank Singhal, page 3 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.